| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Febrile Neutropenia | 3 | 2023 | 16 | 2.370 |
Why?
|
| Bacteremia | 4 | 2022 | 103 | 1.570 |
Why?
|
| Sepsis | 2 | 2023 | 329 | 1.260 |
Why?
|
| Anti-Bacterial Agents | 8 | 2023 | 798 | 1.020 |
Why?
|
| Hospitals, Pediatric | 2 | 2024 | 117 | 1.010 |
Why?
|
| Tertiary Care Centers | 3 | 2024 | 110 | 0.960 |
Why?
|
| Syphilis, Congenital | 1 | 2024 | 6 | 0.950 |
Why?
|
| Clostridium Infections | 3 | 2023 | 125 | 0.860 |
Why?
|
| Blood Culture | 2 | 2020 | 11 | 0.850 |
Why?
|
| Neoplasms | 3 | 2023 | 3065 | 0.820 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2023 | 73 | 0.800 |
Why?
|
| Hypotension | 1 | 2022 | 71 | 0.780 |
Why?
|
| Publishing | 1 | 2022 | 90 | 0.760 |
Why?
|
| Staphylococcal Infections | 2 | 2017 | 272 | 0.740 |
Why?
|
| Pandemics | 3 | 2022 | 778 | 0.740 |
Why?
|
| Public Health | 1 | 2022 | 140 | 0.740 |
Why?
|
| Child | 19 | 2025 | 7242 | 0.720 |
Why?
|
| Fever | 5 | 2022 | 127 | 0.680 |
Why?
|
| Pneumonia, Necrotizing | 1 | 2017 | 1 | 0.570 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 3 | 2019 | 27 | 0.540 |
Why?
|
| Staphylococcus aureus | 2 | 2010 | 278 | 0.540 |
Why?
|
| Bacteria | 1 | 2020 | 486 | 0.530 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 78 | 0.520 |
Why?
|
| Cross Infection | 4 | 2023 | 151 | 0.490 |
Why?
|
| Infant, Newborn | 7 | 2025 | 2498 | 0.470 |
Why?
|
| Humans | 45 | 2025 | 89924 | 0.460 |
Why?
|
| Neutrophils | 3 | 2020 | 311 | 0.460 |
Why?
|
| Child, Preschool | 13 | 2025 | 3769 | 0.420 |
Why?
|
| Leadership | 4 | 2021 | 141 | 0.420 |
Why?
|
| Virulence Factors | 2 | 2010 | 112 | 0.410 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2009 | 5 | 0.400 |
Why?
|
| Retrospective Studies | 9 | 2025 | 9203 | 0.400 |
Why?
|
| Hemolysin Proteins | 2 | 2009 | 34 | 0.400 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2024 | 119 | 0.390 |
Why?
|
| Bacterial Toxins | 2 | 2009 | 114 | 0.380 |
Why?
|
| Adhesins, Bacterial | 1 | 2010 | 36 | 0.360 |
Why?
|
| Adolescent | 11 | 2025 | 9339 | 0.360 |
Why?
|
| Bacterial Adhesion | 1 | 2010 | 84 | 0.350 |
Why?
|
| Proteoglycans | 1 | 2010 | 123 | 0.330 |
Why?
|
| Membrane Transport Proteins | 1 | 2010 | 171 | 0.330 |
Why?
|
| Communicable Diseases | 1 | 2010 | 63 | 0.320 |
Why?
|
| Lung Diseases | 2 | 2009 | 275 | 0.320 |
Why?
|
| Chemokines, CXC | 1 | 2008 | 22 | 0.320 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 28 | 0.320 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 539 | 0.320 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2020 | 151 | 0.310 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2025 | 109 | 0.300 |
Why?
|
| Actinomycosis | 1 | 2008 | 12 | 0.300 |
Why?
|
| Syndecans | 1 | 2007 | 4 | 0.300 |
Why?
|
| HIV Infections | 1 | 2017 | 848 | 0.300 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 237 | 0.290 |
Why?
|
| Drug Utilization | 2 | 2018 | 66 | 0.280 |
Why?
|
| Guideline Adherence | 2 | 2021 | 234 | 0.280 |
Why?
|
| Infection Control | 4 | 2023 | 124 | 0.280 |
Why?
|
| Critical Care | 2 | 2022 | 384 | 0.280 |
Why?
|
| Shock, Septic | 2 | 2023 | 105 | 0.270 |
Why?
|
| Health Personnel | 2 | 2021 | 214 | 0.260 |
Why?
|
| Disease Outbreaks | 2 | 2017 | 156 | 0.260 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2005 | 1 | 0.260 |
Why?
|
| Paragonimiasis | 1 | 2005 | 1 | 0.260 |
Why?
|
| Appendicitis | 1 | 2006 | 66 | 0.250 |
Why?
|
| Caregivers | 2 | 2025 | 167 | 0.240 |
Why?
|
| Infant | 6 | 2025 | 3189 | 0.240 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2024 | 9 | 0.240 |
Why?
|
| Child, Hospitalized | 1 | 2025 | 36 | 0.230 |
Why?
|
| Personal Protective Equipment | 2 | 2021 | 35 | 0.230 |
Why?
|
| Male | 16 | 2025 | 42657 | 0.230 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 654 | 0.230 |
Why?
|
| Triage | 1 | 2025 | 117 | 0.230 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 65 | 0.220 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2023 | 24 | 0.210 |
Why?
|
| Female | 16 | 2025 | 46571 | 0.210 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 107 | 0.210 |
Why?
|
| Inflammation | 2 | 2008 | 981 | 0.210 |
Why?
|
| Machine Learning | 1 | 2025 | 270 | 0.200 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 91 | 0.200 |
Why?
|
| Aftercare | 1 | 2023 | 88 | 0.200 |
Why?
|
| Monocytes | 1 | 2023 | 221 | 0.200 |
Why?
|
| Critical Pathways | 1 | 2022 | 37 | 0.200 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2021 | 48 | 0.190 |
Why?
|
| Hand Hygiene | 1 | 2021 | 10 | 0.190 |
Why?
|
| United States | 7 | 2024 | 7102 | 0.190 |
Why?
|
| Pregnancy | 3 | 2024 | 3040 | 0.190 |
Why?
|
| Inpatients | 2 | 2021 | 312 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 52 | 0.180 |
Why?
|
| Burns | 1 | 2023 | 141 | 0.180 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 437 | 0.180 |
Why?
|
| Infliximab | 2 | 2019 | 159 | 0.180 |
Why?
|
| Patient Discharge | 1 | 2023 | 326 | 0.170 |
Why?
|
| Neutropenia | 1 | 2020 | 214 | 0.170 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 10 | 0.160 |
Why?
|
| Klebsiella Infections | 1 | 2019 | 30 | 0.160 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 40 | 0.160 |
Why?
|
| Syndecan-1 | 2 | 2009 | 18 | 0.160 |
Why?
|
| Expert Testimony | 1 | 2018 | 34 | 0.160 |
Why?
|
| Chagas Disease | 1 | 2018 | 3 | 0.150 |
Why?
|
| Logistic Models | 1 | 2022 | 1214 | 0.150 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 23 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2022 | 351 | 0.150 |
Why?
|
| Leishmaniasis | 1 | 2017 | 4 | 0.150 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2017 | 16 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 919 | 0.140 |
Why?
|
| Directly Observed Therapy | 1 | 2017 | 5 | 0.140 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2017 | 6 | 0.140 |
Why?
|
| Health Resources | 1 | 2018 | 80 | 0.140 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 28 | 0.140 |
Why?
|
| Meglumine | 1 | 2017 | 38 | 0.140 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 32 | 0.140 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2017 | 26 | 0.140 |
Why?
|
| HIV Antibodies | 1 | 2017 | 26 | 0.140 |
Why?
|
| Drug Overdose | 1 | 2018 | 78 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1704 | 0.140 |
Why?
|
| Vancomycin | 1 | 2017 | 73 | 0.130 |
Why?
|
| Adult | 5 | 2025 | 26810 | 0.130 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 6 | 0.130 |
Why?
|
| Sorbitol | 1 | 2016 | 8 | 0.130 |
Why?
|
| Foodborne Diseases | 1 | 2016 | 8 | 0.130 |
Why?
|
| Organometallic Compounds | 1 | 2017 | 137 | 0.130 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 35 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 262 | 0.120 |
Why?
|
| Acute Disease | 1 | 2017 | 846 | 0.120 |
Why?
|
| Social Media | 1 | 2016 | 96 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 151 | 0.120 |
Why?
|
| Genotype | 1 | 2019 | 1853 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 150 | 0.110 |
Why?
|
| Epidermal Cyst | 1 | 2013 | 7 | 0.110 |
Why?
|
| Education, Medical | 1 | 2016 | 243 | 0.110 |
Why?
|
| Young Adult | 3 | 2020 | 6408 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 889 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 451 | 0.110 |
Why?
|
| Meningitis | 1 | 2013 | 21 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3680 | 0.110 |
Why?
|
| Physician's Role | 1 | 2015 | 176 | 0.110 |
Why?
|
| Escherichia coli | 1 | 2016 | 607 | 0.110 |
Why?
|
| Prognosis | 1 | 2020 | 3796 | 0.100 |
Why?
|
| Animals | 7 | 2010 | 27526 | 0.100 |
Why?
|
| Brain Diseases | 1 | 2013 | 187 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2015 | 340 | 0.100 |
Why?
|
| Critical Illness | 2 | 2025 | 311 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 2653 | 0.090 |
Why?
|
| Aspirin | 2 | 2014 | 162 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 2 | 2010 | 740 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2014 | 244 | 0.080 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2009 | 21 | 0.080 |
Why?
|
| Chemokines | 1 | 2008 | 74 | 0.080 |
Why?
|
| Lung Injury | 1 | 2009 | 53 | 0.080 |
Why?
|
| Enterotoxins | 1 | 2008 | 22 | 0.080 |
Why?
|
| Brain Abscess | 1 | 2007 | 8 | 0.080 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2007 | 21 | 0.070 |
Why?
|
| Leishmania | 2 | 2017 | 7 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2010 | 677 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1607 | 0.070 |
Why?
|
| Foreign Bodies | 1 | 2007 | 66 | 0.070 |
Why?
|
| Bronchi | 1 | 2007 | 230 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2677 | 0.070 |
Why?
|
| Risk Factors | 3 | 2023 | 5554 | 0.070 |
Why?
|
| Praziquantel | 1 | 2005 | 1 | 0.060 |
Why?
|
| Anthelmintics | 1 | 2005 | 6 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 3252 | 0.060 |
Why?
|
| Chicago | 2 | 2019 | 1431 | 0.060 |
Why?
|
| Patient Transfer | 1 | 2025 | 99 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1227 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2025 | 344 | 0.050 |
Why?
|
| Health Facilities | 1 | 2023 | 39 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 808 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2023 | 99 | 0.050 |
Why?
|
| Bandages | 1 | 2023 | 42 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2025 | 306 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2025 | 408 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2025 | 358 | 0.050 |
Why?
|
| Parents | 1 | 2025 | 290 | 0.050 |
Why?
|
| Child Care | 1 | 2021 | 9 | 0.050 |
Why?
|
| Hand Disinfection | 1 | 2021 | 17 | 0.050 |
Why?
|
| Personnel, Hospital | 1 | 2021 | 30 | 0.050 |
Why?
|
| Invasive Fungal Infections | 1 | 2020 | 10 | 0.040 |
Why?
|
| Mice | 3 | 2009 | 11851 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 224 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 145 | 0.040 |
Why?
|
| Molecular Typing | 1 | 2019 | 17 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 168 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 13 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 53 | 0.040 |
Why?
|
| Medical Audit | 1 | 2018 | 39 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 171 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 232 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 153 | 0.040 |
Why?
|
| Mexico | 1 | 2018 | 70 | 0.040 |
Why?
|
| Epidemiologists | 1 | 2017 | 1 | 0.040 |
Why?
|
| Public Health Practice | 1 | 2017 | 11 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 387 | 0.040 |
Why?
|
| Public Health Administration | 1 | 2017 | 18 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 384 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 102 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2017 | 65 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 64 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2025 | 2327 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 121 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2016 | 75 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 186 | 0.030 |
Why?
|
| Drug Costs | 1 | 2017 | 63 | 0.030 |
Why?
|
| Food Service, Hospital | 1 | 2016 | 4 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 666 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 748 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 871 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1250 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 841 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 303 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2015 | 50 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1864 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 888 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 466 | 0.030 |
Why?
|
| Viruses | 1 | 2015 | 78 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 944 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 216 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2014 | 143 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 43 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2014 | 192 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2018 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2767 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1601 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 720 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 2887 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 584 | 0.020 |
Why?
|
| Physicians | 1 | 2018 | 691 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2010 | 92 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1394 | 0.020 |
Why?
|
| Craniotomy | 1 | 2007 | 89 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 1008 | 0.020 |
Why?
|
| Drainage | 1 | 2007 | 165 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2007 | 162 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1091 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1576 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 8270 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 811 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 1898 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 1292 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 2015 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 1221 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 3403 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 26132 | 0.010 |
Why?
|